Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer

Mace Rothenberg, Senior Vice President Clinical Development and Medical Affairs, Pfizer Oncology
Mace Rothenberg, chief medical officer of Pfizer Inc.’s oncology unit, is confident that immunotherapy candidates and other pipelines along with new drugs rolled out in the past few years will propel the US giant to one of the top companies in cancer medicines.

“We have a very rich pipeline of what we think are first-in-class or best-in-class compounds,” Dr Rothenberg told Jiho in an interview held in Chicago on the sidelines of the annual meeting of the American Society of Clinical Oncology (ASCO). “We think that with these drugs, we have a very good opportunity to emerge as a leader in oncology, and that would include becoming one of the top companies in oncology worldwide,” he said.

News Calendar